Ayla Ellison

PacBio has promoted an internal veteran to CEO after Christian Henry stepped down , tasking the new leader with improving sales, expanding the DNA sequencing company's clinical reach and cutting costs.

Novo Nordisk's second-quarter earnings results this week were closely watched by analysts and investors eager to see whether the rollout of oral Wegovy could neutralize concerns about the pharma's pipeline.

Elevated medical costs and policy turmoil continued to affect the financial performance of payers and providers in the second quarter.

Having spent 14 years building out its capacity, Regeneron Genetics Center—the genomic research branch of the Tarrytown, New York-based pharma—is

Consumer wearables are popular for a reason. People like to have their health data on demand. These insights can encourage healthy habits and may flag early signals of an underlying illness.

Earnings calls are a chance to catch up with the latest developments across Big Pharma and beyond, and last quarter was no different.

The U.S. is facing a rapidly aging population alongside a dearth of primary care physicians, who play a crucial role in catching health issues early and keeping costs low.

As Fierce Pharma Week approaches, the Fierce Pharma Marketing team is taking stock of some of the biggest trends reshaping how drugmakers and healthc

A genome can be sequenced in days. Medicines are being built around molecular targets the industry wrote off as unreachable a decade ago. Software finds patterns in clinical data no human reader would catch. Researchers are intervening in disease at its genetic source. And yet patients still wait years for a diagnosis. Hospital bills remain indecipherable. Millions of people live too far from a doctor to see one regularly.

Some breakthroughs arrive with an FDA approval. Others show up earlier, when a long-stubborn scientific problem finally starts to give way.This year’s Fierce 50 Breakthrough honorees span that spectrum.